"Not So Different" Episode 7: Oncology Biosimilars

Podcast

Last time on the podcast, we spoke with a practicing rheumatologist about his experience with biosimilars so far, but one of the most exciting prospects on the biosimilars horizon is the market entry of 2 approved anticancer biosimilars: trastuzumab and bevacizumab. This week, we’re delving into the world of supportive care and anticancer biosimilars with an oncology expert, Robert M. Rifkin, MD, FACP.

Last time on the podcast, we spoke with a practicing rheumatologist about his experience with biosimilars so far, but one of the most exciting prospects on the biosimilars horizon is the market entry of 2 approved anticancer biosimilars: trastuzumab and bevacizumab.

This week, we’re delving into the world of supportive care and anticancer biosimilars with an oncology expert, Robert M. Rifkin, MD, FACP.

Rifkin is the medical director of biosimilars at McKesson Specialty Health, part of The US Oncology Network. We caught up with Rifkin last week at the Community Oncology Alliance’s 2018 Community Oncology Conference in National Harbor, Maryland, to talk about experience with biosimilars so far, and what the future holds in this therapeutic area.

Subscribe to "Not So Different" on iTunes.

Related Videos
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumschild, PharmD, MS, MBA
andre harvin
Andre Harvin, PharmD
Nabil Saba
Paul Reider
Sonia T. Oskouei, PharmD, BCMAS, DPLA0
Edward Arrowsmith, MD
Chelsee Jensen, PharmD
Related Content
© 2024 MJH Life Sciences

All rights reserved.